BXPH.F Stock Overview
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.22 |
| 52 Week High | AU$0.50 |
| 52 Week Low | AU$0.0085 |
| Beta | 1.87 |
| 11 Month Change | -0.90% |
| 3 Month Change | -12.00% |
| 1 Year Change | 100.00% |
| 33 Year Change | 340.00% |
| 5 Year Change | 158.82% |
| Change since IPO | 10.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXPH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.3% | 1.6% | 2.2% |
| 1Y | 100.0% | 10.0% | 31.7% |
Return vs Industry: BXPH.F exceeded the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: BXPH.F exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| BXPH.F volatility | |
|---|---|
| BXPH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BXPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BXPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BXPH.F fundamental statistics | |
|---|---|
| Market cap | US$377.95m |
| Earnings (TTM) | -US$9.01m |
| Revenue (TTM) | US$1.34m |
281.0x
P/S Ratio-41.9x
P/E RatioIs BXPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXPH.F income statement (TTM) | |
|---|---|
| Revenue | AU$2.07m |
| Cost of Revenue | AU$3.65m |
| Gross Profit | -AU$1.58m |
| Other Expenses | AU$12.29m |
| Earnings | -AU$13.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | -76.48% |
| Net Profit Margin | -670.20% |
| Debt/Equity Ratio | 0% |
How did BXPH.F perform over the long term?
See historical performance and comparison